Latest News in the pharma Industry

Research & Development

Teva and AbCellera enter into agreement to discover rare monoclonal antibodies

Teva and AbCellera enter into agreement to discover rare monoclonal antibodies

3 Feb 2016

Agreement further supports Teva’s novel biologics development program.

Read more 
New drugs from Abbvie, Gilead, Intercept and Merck forecast to achieve blockbuster status by 2020

New drugs from Abbvie, Gilead, Intercept and Merck forecast to achieve blockbuster status by 2020

3 Feb 2016

Annual ‘Drugs to Watch’ study spotlights seven emerging blockbusters poised to enter the market in 2016.

Read more 
Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine

Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine

2 Feb 2016

Building on the company's successful history in developing vaccines against similar viruses, most recently the introduction of Dengvaxia against dengue, Sanofi Pasteur is launching a Zika vaccine project.

Read more 
BMS and Pfizer sign collaboration with Portola Pharmaceuticals to develop and commercialize investigational andexanet alfa in Japan

BMS and Pfizer sign collaboration with Portola Pharmaceuticals to develop and commercialize investigational andexanet alfa in Japan

1 Feb 2016

Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban).

Read more 
Aragen Bioscience announces ground breaking on state-of-the-art research facility

Aragen Bioscience announces ground breaking on state-of-the-art research facility

1 Feb 2016

The new research space will add 15,000 sq.ft. to Aragen’s existing laboratories and will double capacity for diverse efficacy studies.

Read more 
BMS and AbbVie receive positive CHMP opinion for investigational antibody, Empliciti, for the treatment of multiple myeloma

BMS and AbbVie receive positive CHMP opinion for investigational antibody, Empliciti, for the treatment of multiple myeloma

29 Jan 2016

Positive opinion based on reduction in the risk of disease progression or death with Empliciti in combination with standard of care regimen for multiple myeloma demonstrated in ELOQUENT-2 study.

Read more 
Allergan and AstraZeneca collaborate to develop and commercialize ATM-AVI for antibiotic-resistant gram-negative infections

Allergan and AstraZeneca collaborate to develop and commercialize ATM-AVI for antibiotic-resistant gram-negative infections

29 Jan 2016

ATM-AVI is an investigational, fixed-dose antibiotic combining aztreonam and avibactam.

Read more 
Boehringer Ingelheim's Gilotrif demonstrated superiority to Iressa

Boehringer Ingelheim's Gilotrif demonstrated superiority to Iressa

27 Jan 2016

Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib is superior in reducing the risk of lung cancer progression and the risk of treatment failure both by 27% compared to gefitinib.

Read more 
Ixchelsis announces positive clinical proof of concept results for IX-01 in treating premature ejaculation

Ixchelsis announces positive clinical proof of concept results for IX-01 in treating premature ejaculation

25 Jan 2016

The drug was also shown to be extremely well tolerated with a safety and adverse event profile similar to that seen for placebo.

Read more 
Fc receptor protein collection

Fc receptor protein collection

25 Jan 2016

Recombinant Fc Receptor proteins from AMSBIO are uniquely suitable for pharmaceutical research.

Read more 
Shire resubmits NDA for lifitegrast to FDA

Shire resubmits NDA for lifitegrast to FDA

25 Jan 2016

Resubmission includes positive data from OPUS-3, a Phase III efficacy and safety trial.

Read more 
FDA accepts filing of cardiovascular outcomes data for Jardiance

FDA accepts filing of cardiovascular outcomes data for Jardiance

25 Jan 2016

Boehringer Ingelheim and Eli Lilly and Company expect to receive a decision from the FDA within the standard review time frame.

Read more